The DOI matches its Crossref record; the references it cites are not checked yet.
Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)
Open accessAbstract
Background Remission of type 2 diabetes can occur as a result of weight loss and is characterised by liver fat and pancreas fat reduction and recovered insulin secretion. In this analysis, we aimed to investigate the mechanisms of weight loss- induced remission in people with prediabetes.Methods In this prespecified post-hoc analysis, weight loss-induced resolution of prediabetes in the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS) was assessed, and the results were validated against participants from the Diabetes Prevention Program (DPP) study. For PLIS, between March 1, 2012, and Aug 31, 2016, participants were recruited from eight clinical study centres (including seven university hospitals) in Germany and randomly assigned to receive either a control intervention, a standard lifestyle intervention (ie, DPP-based intervention), or an intensified lifestyle intervention for 12 months. For DPP, participants were recruited from 23 clinical study centres in the USA between July 31, 1996, and May 18, 1999, and randomly assigned to receive either a standard lifestyle intervention, metformin, or placebo. In both PLIS and DPP, only participants who were randomly assigned to receive lifestyle intervention or placebo and who lost at least 5% of their bodyweight were included in this analysis. Responders were defined as people who returned to normal fasting plasma glucose (FPG; <5·6 mmol/L), normal glucose tolerance (<7·8 mmol/L), and HbA 1c less than 39 mmol/mol after 12 months of lifestyle intervention or placebo or control intervention. Non-responders were defined as people who had FPG, 2 h glucose, or HbA 1c more than these thresholds. The main outcomes for this analysis were insulin sensitivity, insulin secretion, visceral adipose tissue (VAT), and intrahepatic lipid content (IHL) and were evaluated via linear mixed models.Findings Of 1160 participants recruited to PLIS, 298 (25·7%) had weight loss of 5% or more of their bodyweight at baseline. 128 (43%) of 298 participants were responders and 170 (57%) were non-responders. Responders were younger than non-responders (mean age 55·6 years [SD 9·9] vs 60·4 years [8·6]; p<0·0001). The DPP validation cohort included 683 participants who lost at least 5% of their bodyweight at baseline. Of these, 132 (19%) were responders and 551 (81%) were non-responders. In PLIS, BMI reduction was similar between responders and non-responders (responders mean at baseline 32·4 kg/m 2 [SD 5·6] to mean at 12 months 29·0 kg/m 2 [4·9] vs non-responders 32·1 kg/m 2 [5·9] to 29·2 kg/m 2 [5·4]; p=0·86). However, whole-body insulin sensitivity increased more in responders than in non-responders (mean at baseline 291 mL/[min × m 2], SD 60 to mean at 12 months 378 mL/[min × m 2], 56 vs 278 mL/[min × m 2], 62, to 323 mL/[min × m 2], 66; p<0·0001), whereas insulin secretion did not differ within groups over time or between groups (responders mean at baseline 175 pmol/mmol [SD 64] to mean at 12 months 163·7 pmol/mmol [60·6] vs non-responders 158·0 pmol/mmol [55·6] to 154·1 pmol/mmol [56·2]; p=0·46). IHL decreased in both groups, without a difference between groups (responders mean at baseline 10·1% [SD 8·7] to mean at 12 months 3·5% [3·9] vs non-responders 10·3% [8·1] to 4·2% [4·2]; p=0·34); however, VAT decreased more in responders than in non-responders (mean at baseline 6·2 L [SD 2·9] to mean at 12 months 4·1 L [2·3] vs 5·7 L [2·3] to 4·5 L [2·2]; p=0·0003). Responders had a 73% lower risk of developing type 2 diabetes than non-responders in the 2 years after the intervention ended.Interpretation By contrast to remission of type 2 diabetes, resolution of prediabetes was characterised by an improvement in insulin sensitivity and reduced VAT. Because return to normal glucose regulation (NGR) prevents development of type 2 diabetes, we propose the concept of remission of prediabetes in analogy to type 2 diabetes. We suggest that remission of prediabetes should be the primary therapeutic aim in individuals with prediabetes.Funding German Federal Ministry for Education and Research via the German Center for Diabetes Research; the Ministry of Science, Research and the Arts Baden-Württemberg; the Helmholtz Association and Helmholtz Munich; the Cluster of Excellence Controlling Microbes to Fight Infections; and the German Research Foundation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a post-hoc analysis of the Prediabetes Lifestyle Intervention Study (PLIS) suggested that patients achieving prediabetes remission differed from non-responders in improvement in whole body insulin sensitivity, visceral adipose tissue (VAT) and intrahepatic fat rather than insulin secretion upon a similar weight loss76”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [76]
In the citing paper
“To date, remission of T2D has been associated by reduction of liver and pancreas ectopic fat accumulation and restored insulin secretion76”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [76]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 67 · Cited by 100
Metadata
- Authors
- Sandforth, A., von Schwartzenberg, R. J., Arreola, E. V., Hanson, R. L., Sancar, G., Katzenstein, S., Lange, K., Preißl, H., Dreher, S. I., Weigert, C., Wagner, R., Kantartzis, K., Machann, J., Schick, F., Lehmann, R., Peter, A., Katsouli, N., Ntziachristos, V., Dannecker, C., Fritsche, L., Perakakis, N., Heni, M., Nawroth, P. P., Kopf, S., Pfeiffer, A. F. H., Kabisch, S., Stumvoll, M., Schwarz, P. E. H., Hauner, H., Lechner, A., Seissler, J., Yurchenko, I., Icks, A., Solimena, M., Häring, H.-U., Szendroedi, J., Schürmann, A., de Angelis, M. H., Blüher, M., Roden, M., Bornstein, S. R., Stefan, N., Fritsche, A., & Birkenfeld, A. L.
- Affiliations
- Helmholtz Munich (DE)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Düsseldorf University Hospital (DE)
- German Center for Diabetes Research (DE)
- University Hospital Heidelberg (DE)
- Deutsches Diabetes-Zentrum e.V. (DE)
- King's College London (GB)
- Corresponding author
- Birkenfeld, Andreas L
- ORCID
- Sandforth, Arvid
- Arreola, Elsa Vazquez
- Hanson, Robert L
- Sancar, Gencer
- Preißl, Hubert
- Dreher, Simon I
- Weigert, Cora
- Wagner, Robert
- Machann, Jürgen
- Schick, Fritz
- Lehmann, Rainer
- Peter, Andreas
- Katsouli, Nikoletta
- Ntziachristos, Vasilis
- Dannecker, Corinna
- Fritsche, Louise
- Perakakis, Nikolaos
- Heni, Martin
- Nawroth, Peter Paul
- Kopf, Stefan
- Pfeiffer, Andreas F H
- Kabisch, Stefan
- Schwarz, Peter E H
- Hauner, Hans
- Lechner, Andreas
- Seissler, Jochen
- Icks, Andrea
- Solimena, Michele
- Häring, Hans-Ulrich
- Szendroedi, Julia
- Schürmann, Annette
- Blüher, Matthias
- Roden, Michael
- Bornstein, Stefan R
- Stefan, Norbert
- Fritsche, Andreas
- Birkenfeld, Andreas L
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 11
- Issue
- 11
- Pages
- 798-810
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4387006645
- Cited by
- 100
- References
- 67
- Citations by year
- 2026: 36 · 2025: 33 · 2024: 25 · 2023: 6
- FWCI
- 20.37
- Type
- journal article
- Language
- en
- Update notices
- erratum (2024-01-01)
- Open access
- green
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bundesministerium für Bildung und Forschung (01GI0925)
- National Institute of Diabetes and Digestive and Kidney Diseases
- BMBF Berlin
- National Institute of Child Health and Human Development
- Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (VH-NG-1619)
- Office of Research on Women's Health
- Centers for Disease Control and Prevention
- Deutsche Forschungsgemeinschaft (GRK2816)
- Eberhard Karls Universität Tübingen
- National Institute on Aging
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- prediabetes remission, type 2 diabetes prevention, weight loss, lifestyle intervention, insulin sensitivity, insulin secretion, visceral adipose tissue, intrahepatic lipid, liver fat, fasting blood glucose, HbA1c, Diabetes Prevention Program, metformin, hepatic insulin sensitivity, beta-cell function
- MeSH terms
- Body Weight, Diabetes Mellitus, Type 2, Glucose, Humans, Insulin Resistance, Life Style, Middle Aged, Prediabetic State, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). https://app.cochat.ai/papers/10.1016/s2213-8587(23)00235-8
- The paper
- Sandforth, A., von Schwartzenberg, R. J., Arreola, E. V., Hanson, R. L., Sancar, G., Katzenstein, S., Lange, K., Preißl, H., Dreher, S. I., Weigert, C., Wagner, R., Kantartzis, K., Machann, J., Schick, F., Lehmann, R., Peter, A., Katsouli, N., Ntziachristos, V., Dannecker, C., . . . Birkenfeld, A. L. (2023). Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00235-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.